Tessa Romero
Stock Analyst at JP Morgan
(1.1)
# 1210
Out of 5,312 analysts
63
Total ratings
39.53%
Success rate
12.11%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
DYN Dyne Therapeutics | Maintains: Neutral | 18 17 | 6.79 | 150.37% | 5 | Mar 21, 2025 | |
BHVN Biohaven | Maintains: Overweight | 72 68 | 17.18 | 295.81% | 6 | Mar 5, 2025 | |
UPB Upstream Bio | Initiates Coverage On: Overweight | 38 | 6.8 | 458.82% | 1 | Nov 5, 2024 | |
NMRA Neumora Therapeutics | Downgrades: Neutral | 18 15 | 0.65 | 2207.69% | 4 | Nov 5, 2024 | |
MCRB Seres Therapeutics | Downgrades: Underweight | n/a | n/a | n/a | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 31 | 26.62 | 16.45% | 5 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 71 | 36.82 | 92.83% | 4 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 32 29 | 4.83 | 500.41% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 31 | 11.29 | 174.58% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 46 | 25.65 | 79.34% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 29 25 | 14.06 | 77.81% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 1.9 | 952.63% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 8 7 | 4.54 | 54.19% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 54 55 | 30.12 | 82.6% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 39 36 | n/a | n/a | 4 | Jun 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 140 150 | n/a | n/a | 1 | Mar 2, 2021 |